AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2025-07-11T16:49:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Cathie Wood's ARK Dumps $26 Million Palantir Shares, Bulks Up on Airbnb
Fri 16 May 25, 04:22 PMTwist Bioscience to Present at William Blair 45th Annual Growth Stock Conference
Thu 15 May 25, 12:00 PMTwist Bioscience Corporation Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Tue 13 May 25, 12:00 PMTwist Bioscience and Ginkgo Bioworks Revise Collaboration
Thu 08 May 25, 12:00 PMTwist Bioscience Second Quarter 2025 Earnings: EPS Misses Expectations
Tue 06 May 25, 10:23 AMQ2 2025 Twist Bioscience Corp Earnings Call
Tue 06 May 25, 05:18 AMTwist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Mon 05 May 25, 12:25 PMTwist Bioscience Announces Fiscal 2025 Second Quarter Financial Results
Mon 05 May 25, 11:15 AMTwist Bioscience Spins Out DNA Data Storage as Independent Company
Mon 05 May 25, 11:10 AM| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | -203.46600M | -228.27400M | -154.02800M | -139.54900M | -107.37700M |
| Minority interest | - | - | - | - | - |
| Net income | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
| Selling general administrative | 189.74M | 212.95M | 135.90M | 103.27M | 80.13M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 89.73M | 84.23M | 51.71M | 28.69M | 6.96M |
| Reconciled depreciation | - | 16.51M | 9.75M | 6.68M | 6.11M |
| Ebit | -217.15900M | -249.02100M | -153.26000M | -117.57900M | -108.85000M |
| Ebitda | -193.20500M | -247.04600M | -154.19500M | -116.26200M | -106.08300M |
| Depreciation and amortization | 23.95M | 1.98M | -0.93500M | 1.32M | 2.77M |
| Non operating income net other | - | 6.58M | -0.93500M | 1.32M | 2.77M |
| Operating income | -217.15900M | -249.02100M | -153.26000M | -117.57900M | -108.85000M |
| Other operating expenses | 452.01M | 452.59M | 285.59M | 207.68M | 163.24M |
| Interest expense | 0.00500M | 0.08M | 0.37M | 0.79M | 1.29M |
| Tax provision | 1.15M | -10.41100M | -1.93000M | 0.38M | 0.29M |
| Interest income | 14.37M | 3.06M | 0.43M | 1.50M | 3.03M |
| Net interest income | 14.36M | 2.98M | 0.07M | 0.71M | 1.74M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | 22.50M | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.15M | -10.41100M | -1.93000M | 0.38M | 0.29M |
| Total revenue | 245.11M | 203.56M | 132.33M | 90.10M | 54.38M |
| Total operating expenses | 296.63M | 333.26M | 204.97M | 146.27M | 115.81M |
| Cost of revenue | 155.38M | 119.33M | 80.62M | 61.41M | 47.43M |
| Total other income expense net | -10.92300M | 20.75M | -0.76800M | -21.97000M | 1.47M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
| Net income applicable to common shares | - | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 776.40M | 961.38M | 702.10M | 398.88M | 186.99M |
| Intangible assets | 54.48M | 59.74M | 18.26M | 0.31M | 0.51M |
| Earning assets | - | - | - | - | - |
| Other current assets | 11.72M | 11.91M | 8.28M | 6.20M | 2.59M |
| Total liab | 152.97M | 171.99M | 121.28M | 62.62M | 34.91M |
| Total stockholder equity | 623.43M | 789.38M | 580.82M | 336.26M | 152.08M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 7.80M | 53.45M | 9.62M | 2.61M | 0.82M |
| Common stock | - | 789.38M | 580.82M | 336.26M | -186.99400M |
| Capital stock | - | 0.00000M | 0.00000M | 0.00000M | 0.00000M |
| Retained earnings | -1033.03400M | -828.41600M | -610.55300M | -458.45500M | -318.52400M |
| Other liab | - | 0.06M | 5.07M | 0.35M | 0.16M |
| Good will | 85.81M | 85.81M | 22.43M | 1.14M | 1.14M |
| Other assets | - | -0.00100M | 49.90M | 3.40M | 4.38M |
| Cash | 286.47M | 378.69M | 465.83M | 93.67M | 46.73M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 73.32M | 90.66M | 63.05M | 36.03M | 30.35M |
| Current deferred revenue | 36.57M | 3.48M | 28.76M | 18.85M | 16.44M |
| Net debt | -192.40100M | -283.77500M | -402.90800M | -57.68500M | -39.00200M |
| Short term debt | 14.90M | 13.64M | 9.77M | 9.74M | 3.33M |
| Short long term debt | - | - | 1.55M | 3.33M | 3.33M |
| Short long term debt total | 94.07M | 94.91M | 62.92M | 35.98M | 7.73M |
| Other stockholder equity | 1657.22M | 1619.64M | 1190.83M | 794.63M | 283.43M |
| Property plant equipment | - | 214.39M | 44.12M | 25.47M | 20.84M |
| Total current assets | 424.26M | 596.48M | 546.50M | 334.87M | 160.13M |
| Long term investments | - | - | - | - | - |
| Net tangible assets | - | 789.38M | 540.12M | 334.82M | 150.44M |
| Short term investments | 49.94M | 126.28M | 12.03M | 196.34M | 91.37M |
| Net receivables | 44.06M | 40.29M | 28.55M | 26.38M | 12.10M |
| Long term debt | - | - | - | 1.40M | 4.40M |
| Inventory | 32.06M | 39.31M | 31.80M | 12.29M | 7.33M |
| Accounts payable | 14.05M | 20.09M | 14.90M | 4.83M | 9.76M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.75600M | -1.84300M | 0.55M | 0.09M | 0.18M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | - | - | - |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -828.41600M | -610.55300M | -458.45500M | -318.52400M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 8.49M | 4.96M | 9.20M | 3.40M | 4.38M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 352.15M | 364.89M | 155.60M | 64.01M | 26.86M |
| Capital lease obligations | 94.07M | 94.91M | 61.37M | 31.25M | - |
| Long term debt total | - | - | - | 1.40M | 4.40M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | - | -117.15800M | 183.70M | -104.78200M | -90.07400M |
| Change to liabilities | - | 7.38M | 19.02M | -1.71100M | 12.30M |
| Total cashflows from investing activities | - | -232.93000M | 156.16M | -114.65000M | -104.81000M |
| Net borrowings | - | -1.55800M | -3.33300M | -3.33300M | -2.50000M |
| Total cash from financing activities | 0.91M | 270.53M | 329.18M | 303.73M | 158.58M |
| Change to operating activities | - | 4.42M | 3.77M | -0.44200M | 7.71M |
| Net income | -204.61800M | -217.86300M | -152.09800M | -139.93100M | -107.66900M |
| Change in cash | -90.97800M | -87.10000M | 373.11M | 46.85M | -34.13900M |
| Begin period cash flow | 380.26M | 467.36M | 94.25M | 47.40M | 81.54M |
| End period cash flow | 289.28M | 380.26M | 467.36M | 94.25M | 47.40M |
| Total cash from operating activities | -142.47400M | -124.38500M | -112.24400M | -142.25500M | -87.93700M |
| Issuance of capital stock | - | 269.82M | 323.86M | 295.56M | 156.21M |
| Depreciation | 29.31M | 16.51M | 9.75M | 6.68M | 6.11M |
| Other cashflows from investing activities | - | -13.91500M | -0.48300M | - | 0.02M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | 7.24M | -7.53600M | -19.48900M | -4.95600M | -1.30200M |
| Change to account receivables | -4.32000M | -9.62200M | -2.20200M | -14.27200M | -6.68500M |
| Sale purchase of stock | -4.40500M | -7.75400M | -10.84900M | -2.42100M | 161.08M |
| Other cashflows from financing activities | 5.32M | 10.02M | 19.50M | 13.92M | 4.87M |
| Change to netincome | - | 82.32M | 37.10M | 17.25M | 11.59M |
| Capital expenditures | 27.78M | 101.86M | 27.06M | 9.87M | 14.76M |
| Change receivables | - | -9.62200M | -2.20200M | -14.27200M | -6.68500M |
| Cash flows other operating | - | 10.67M | -5.00200M | -5.28000M | -1.31800M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | -86.78100M | 373.09M | 46.83M | -34.16900M |
| Change in working capital | 0.41M | -5.35600M | -9.38100M | -25.17600M | 3.00M |
| Stock based compensation | 30.28M | 79.66M | 37.00M | 17.10M | 11.17M |
| Other non cash items | 2.56M | 2.66M | 1.86M | -0.70700M | 0.52M |
| Free cash flow | -170.25300M | -226.24200M | -139.30500M | -152.12300M | -102.69400M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience Corp |
-0.48 1.25% | 37.99 | - | - | 6.76 | 3.01 | 5.93 | -9.0167 |
| TMO Thermo Fisher Scientific Inc |
5.27 1.22% | 436.00 | 34.71 | 23.87 | 4.62 | 4.43 | 5.29 | 20.89 |
| DHR Danaher Corporation |
-0.01 0.0049% | 205.50 | 29.09 | 28.01 | 5.67 | 3.20 | 6.00 | 19.09 |
| A Agilent Technologies Inc |
-1.275 1.03% | 122.89 | 34.36 | 26.39 | 6.59 | 7.14 | 6.78 | 23.56 |
| IDXX IDEXX Laboratories Inc |
-10.83 2.00% | 530.26 | 49.99 | 45.66 | 11.29 | 27.85 | 11.46 | 34.46 |
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
681 Gateway Boulevard, South San Francisco, CA, United States, 94080
| Name | Title | Year Born |
|---|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Chairman & CEO | 1973 |
| Dr. Patrick John Finn Ph.D. | Pres & COO | 1972 |
| Mr. James M. Thorburn | Chief Financial Officer | 1956 |
| Dr. William Charles Banyai Ph.D. | Sr. VP of Advanced Devel., GM of Data Storage & Director | 1955 |
| Mr. Kevin B. Yankton | VP & Chief Accounting Officer | 1967 |
| Mr. Siyuan Chen | Chief Technology Officer | NA |
| Dr. Aaron K. Sato Ph.D. | Chief Scientific Officer | NA |
| Mr. Dennis Cho | Sr. VP, Gen. Counsel, Chief Ethics & Compliance Officer | 1971 |
| Ms. Paula Green | Sr. VP of HR | 1968 |
| Ms. Erin Smith | Sr. VP of Gov. Affairs & Public Policy | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...